Genzyme Articles
Phase II study of Genzyme’s oral Gaucher's disease drug eliglustat yields positive results
5 May 2010
Two different stories as US biotechs Amgen and Genzyme post first-quarter 2010 results
22 April 2010
US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties
25 March 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Shire presents strong Ph III velaglucerase alfa data in Type 1 Gaucher disease and Genzyme Ph II with eliglustat at LDN meeting
12 February 2010
Targeted Genetics gets $7 million milestone under deal with Genzyme, and another from AMT
11 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Impax Labs sued by Daiichi Sankyo and Genzyme after challenging Welchol patent in USA
18 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Genzyme manufacturing woes hit sales; Amgen forecasts lower-end of expectations EPS and signs deal with MedGenisis
13 January 2010
Pfizer to pay Protalix up to $115 million in Gaucher's disease treatment deal; Genzyme’s Cerezyme supply
2 December 2009
Shire’s Gaucher disease drug enters fast-track EU approval process
27 November 2009
Meeting highlights from Europe’s CHMP November 16-19, 2009
23 November 2009
Genzyme’s woes continue as it drops investigational APB follow-up for Renvela, after poor trial results
19 November 2009
More bad news for Genzyme as US FDA delays Lumizyme application
17 November 2009
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Genzyme updates on Cerezyme and Fabrazyme sales now supply back on line
24 September 2009
Osiris shares plunge after Prochymal disappointment
11 September 2009
Genzyme’s Mozobil gains European Approval
6 August 2009
TWST releases biotech investment report
9 June 2009
Genzyme and Isis meet cholesterol trial endpoint
26 May 2009
Ergomed teams with Genzyme for oncology drug
7 May 2009
Genzyme fails to meet expectations for 1st qtr
27 April 2009
Isis Pharma good buy in tough market; Zacks
9 April 2009
Genzyme sues Impax over Renvela patent
7 April 2009
Osiris shares plunge as Crohn's trial cut short
31 March 2009
Genzyme's Renvela gets nod for expanded EU label
30 March 2009
Genzyme warned plant does not meet cGMP
23 March 2009
Mozobil drug lag reviewed in Japan
23 March 2009
US approval of Genzyme
9 March 2009
Stock Commentary - New York week to Mar 2, 2009
9 March 2009
FDA issues warning letter on Genzyme facility
9 March 2009
FDA approves Genzyme's Geel Myozyme facility
9 March 2009
Genzyme to move Gaucher drug to Ph III
2 March 2009
Positive opinion on Genzyme's Myozyme
2 March 2009
Genzyme's 2008 profit down on costs
23 February 2009
EMEA prioriatizes Myozyme access
26 January 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Stock Commentary - New York week to Jan 12, 2009
19 January 2009
DxS expands EGFR test license with Genzyme
19 January 2009
Genzyme/Isis begin three mipomersen trials
19 January 2009
Mozobil appro for stem cell transplantation
22 December 2008
FDA panel backs Genzyme's Synvisc-One for OA pain
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
Ceregene PD drug fails to beat placebo in trial
1 December 2008
Acelerated appro for Myozyme produced at the 2000 L Bioreactor Scale
24 November 2008
Genzyme enters neglected diseases R&D accord with ICGEB
24 November 2008
Osiris signs up to $1.68B deal with Genzyme
10 November 2008
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Promising Ph II data for Genzyme/Bayer's alemtuzumab
27 October 2008
Pervasis names Frederic Chereau as CEO
27 October 2008
CLARIFICATION: Genzyme's Campath Ph II trial results
27 October 2008
Genzyme's Campath does well in Ph II CLL trial
20 October 2008
KaloBios raises $20M financing
29 September 2008
Enobia names new VPs: Julie Smith and Javant Aphale
29 September 2008
Genzyme announces global R&D expansion
29 September 2008
Takeda US appoints Gregory Landes as VP of antibody research
15 September 2008
Amgen initiates Ph III Aranesp study in HF
18 August 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
Genzyme buys drug rights for up to $437M
28 July 2008
Stock Commentary - New York week to July 14, 2008
21 July 2008
Isis completes licensing of mipomersen to Genzyme
30 June 2008
Altus Pharma appoints new CEO
2 June 2008
BioMarin's 1st-qtr beats analyst expectations
12 May 2008
Merck & Co shares fall 5.1% after
5 May 2008
Isis advised on new drug's approval path
5 May 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Genzyme to set up R&D facility in China
28 April 2008
Genzyme withdraws Evoltra label extension
31 March 2008
Reduced dosage temptation for expensive Gaucher's drug
24 March 2008
Carticel improvement sustained for 10 years
17 March 2008
Genzyme debuts Renvela for US dialysis patients
10 March 2008
Stock Commentary - New York week to Feb 18, 2008
25 February 2008
Genzyme's 4th-qtr 2007 revenue jumps 21%
25 February 2008
Genzyme to develop NSCLC therapy response assay
21 January 2008
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
